LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Featuring Eli Lilly, Pfizer, Johnson & Johnson, Novartis & More - ResearchAndMarkets.com
Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.
- Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.
- This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation.
- The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028.
- Additionally, The UAE market would register a CAGR of 7% during (2022-2028).